TO THE EDITOR
RNA interference (RNAi) is a cellular mechanism that utilizes the ability of double-stranded RNA (dsRNA) to interfere with homologous gene expression at the RNA or DNA level. Recent developments in the use of small interfering RNA (siRNA) to inhibit specific gene expression in mammalian cells have highlighted the potential of these molecules as a therapeutic agent (reviewed in Novina and Sharp 1 ). Fusion transcripts encoding oncogenic proteins such as Bcr-abl represent ideal targets for a disease-specific RNAi approach. There are different clinically relevant bcr-abl transcript variants: in about 95% of the CML patients, the bcr-abl fusion transcripts e14a2 (former b3a2) and e13a2 (former b2a2) can be detected. The translated product is in each case a p210 kDa Bcr-abl protein. In patients with Ph þ ALL, a shorter transcript version called bcr-abl-e1a2 predominates (reviewed in Kurzrock et al 2 ) . Translation of this variant results in the somewhat smaller p190 kDa Bcr-abl protein. The possibility to use RNAi for the selective degradation of the bcr-abl-e14a2 transcript variant has been demonstrated recently. [3] [4] [5] [6] Nevertheless, it is unclear so far whether the expression of the other two relevant bcr-abl transcripts (e13a2 and e1a2) can also be similarly downregulated. We therefore investigated the activity of a panel of siRNAs directed to the bcrabl transcript variants e13a2 and e1a2.
We used two murine hematopoietic 32D cell line derivatives expressing either p210
Bcr-abl (e13a2) or p190 Bcr-abl (e1a2) to study the effectiveness of siRNA treatment in silencing each of these human bcr-abl fusion genes. The 32Dp210/e13a2 and the 32Dp190/e1a2 cell lines were generated by transfection of the parental cells with the retroviral vectors pSRaMSVtkneop210
Bcr-abl (e13a2), which was a generous gift of BJ Druker, MD, Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute, Portland, USA and pSRaMSVtkneo-p190
Bcr-abl (e1a2), which was kindly provided by T Skorski, MD, PhD, DSc, Temple University, Philadelphia, USA. All siRNAs used were directed to the fusion site of the bcr and abl sequences within the respective bcr-abl transcripts (Table 1) . siRNAs were transfected using electroporation as described. 5 RNAi efficiency was assayed via analysis of Bcr-abl protein levels and by monitoring the biological effect using MTT viability assay.
To identify effective siRNAs for inhibition of the CMLassociated fusion gene bcr-abl-e13a2, we treated 32Dp210/ e13a2 cells with four siRNAs (BAF3, BAF15, BAF17 and BAF19) targeting slightly different sequences of the bcr-abl-e13a2 mRNA ( Table 1) . As a control, we used an siRNA directed to the bcr-abl-e14a2 fusion sequence (BAF9). Treatment with BAF3, BAF15, BAF17 and BAF19 revealed significantly different RNAi efficiencies. Repeated electroporation of the siRNAs BAF15 and BAF19 led to effective downregulation of Bcr-abl protein levels (Figure 1a) . Despite the considerable overlap in their target sequence, BAF17 and BAF3 were not active at all. These results were mirrored when studying the biological effect of the bcr-abl RNAi using a MTT viability assay. Three consecutive treatments of 32Dp210/e13a2 with the effective siRNAs BAF15 and BAF19 resulted in an almost complete loss of The exact bcr-abl fusion site is marked by hyphen; s: sense strand; as: antisense strand; DG: free energy values. Thermodynamic properties of siRNA ends were calculated as described. 8 The contribution of dangling ends was calculated as described. 10 viability (Figure 1b) . At 48 h following the third treatment, residual cell viability was only 9.7% (BAF15) and 13.6% (BAF19) of the electroporation control (EPC). Of note, siRNAs that were ineffective in the downregulation of Bcr-abl protein levels (eg BAF3, BAF9 and BAF17) also had no significant effect on cell viability (Figure 1b ). BAF19 siRNA effectively silenced endogenous bcr-abl-e13a2 expression also in MEG-01, a human megakaryocytic CML cell line. When treated three times with BAF19, the cells showed a significant loss of Bcr-abl protein levels compared to control cells (data not shown). Here, too, downregulation of Bcr-abl by RNAi caused substantial loss of viability: in MEG-01 cells treated three times with BAF19, viability was reduced to B28% compared to the EPC (data not shown).
The Bcr-abl variant p190 Bcr-abl (e1a2) can be detected in 20-50% of adult patients with Ph þ ALL and in approximately 90% of children with Ph þ ALL (reviewed in Kurzrock et al 2 ). To assess whether this bcr-abl fusion site may also serve as a target for RNAi, we treated 32Dp190/e1a2 cells twice with two different sequence-specific siRNAs (BAF22 and BAF24; see Table 1 ). As controls, we used siRNAs directed to bcr-abl-e14a2 (BAF9) and bcr-abl-e13a2 (BAF19). BAF22 was found to be effective: repeated treatment at intervals of 24 h with this siRNA led to significant downregulation of Bcr-abl protein levels (Figure 2a) , whereas BAF24 had no effect. In 32Dp190/e1a2 cells reduction of Bcr-abl protein levels by two treatments with BAF22 siRNA resulted in a reduction of viability to 15% relative to the control (EPC) (Figure 2b) .
In summary, we have been able to achieve substantial knockdown not only of bcr-abl-e14a2 as reported previously 5 but also of the two other clinically relevant forms: bcr-abl-e13a2 and bcr-abl-e1a2. Effective downregulation of Bcr-abl required prolonged exposure to siRNA. Reduction of Bcr-abl protein levels via RNAi consistently resulted in loss of viability.
Apparently, siRNA efficiency varied extremely, even though the target regions of the different siRNAs used in our experiments exhibited considerable overlap. For example, the target sequence of the bcr-abl-e13a2-specific siRNA BAF3 is shifted only two nucleotides downstream into the abl part of the fusion site compared to BAF15. Nevertheless, in contrast to BAF15, BAF3 is completely ineffective. The same is true for the bcr-abl-e1a2-specific siRNAs BAF22 and BAF24. The sequence of BAF24 is quite similar to that of BAF22, shifted only by three nucleotides further into the abl region of the fusion transcript; yet, BAF22 actively silences bcr-abl-e1a2 gene expression, whereas BAF24 does not. This might be due to secondary structures in the mRNA, which limit the accessibility of the siRNAs to their target, as has been described previously for the bcr-abl-e14a2 fusion sequence. 7 Overall, we noted a tendency that those siRNAs whose sequences reached further than position þ 12 (downstream of the exact fusion point) into the abl part of the bcr-abl fusion sequence were ineffective. Recently, the influence of the thermodynamic stability of siRNA ends on silencing activity was described in two independent papers. siRNAs with the 5 0 -end of the antisense strand being less stable than the 5 0 -end of the sense strand were shown to be more active. 8, 9 As shown in Table 1 , BAF3 and BAF15 do not differ significantly in the DDG values ( þ 1.8 and þ 2.4 kcal/mol, respectively), but the 5 0 -end of the antisense strand is significantly more stable in BAF3 than in BAF15 (À10.1 vs À7.8 kcal/mol), which could explain the better performance of One of two tested bcr-abl-e1a2-specific siRNAs efficiently induces RNAi. In all, B4 Mio 32Dp190/e1a2 cells have been electroporated twice at intervals of 24 h with the indicated siRNA. BAF22/BAF24: bcr-abl-e1a2-specific siRNAs; BAF9: bcr-abl-e14a2-specific siRNA, served as control; BAF19: bcr-abl-e13a2-specific siRNA, served as control; EPC: electroporation control. 
0 -end of the antisense strand compared to À12.2 kcal/mol for BAF24. In addition, the 5 0 -end of the antisense strand is much weaker than the 5 0 -end of the sense strand (À7.8 vs À12.1 kcal/ mol). According to the current models for siRNA activity, the thermodynamic properties of BAF22 can explain its superior activity compared to BAF24.
In conclusion, the relatively high frequency of effective siRNA sequences observed in our experiments further supports the idea that translocations associated with human leukemias may serve as attractive targets for strategies applying RNAi.
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One of the authors (H-P Vornlocher) is employed by a company (Alnylam Europe AG) whose potential product (bcr-abl siRNA) was studied in this work. 1 These neoplasms have an increasing incidence in Western countries, where they account for about 75% of all lymphoid neoplasms. Therapeutic options for mature B-cell neoplasms include alkylating agents, purine nucleoside analogues, combination chemotherapy, interferon, and monoclonal antibodies. Although most patients respond to chemotherapy, these neoplasms are characterized by a continuous pattern of relapse and there is no standard treatment. [2] [3] [4] Moreover, current chemotherapeutic agents are not selective for tumor cells and consequently they have several negative effects on the quality of life of those treated. For instance, purine analogues induce apoptosis of T cells, which leads to immunosuppression. Thus, new therapeutic drugs with a differential effect on B and T lymphocytes are of great interest.
Blood samples from patients with peripheral blood manifestation of the disease contain both tumor and normal lymphocytes. Thus, analysis of drug-induced apoptosis in the B-cell and T-cell population by flow cytometry is a useful method to study the cell-type selectivity of anticancer drugs or combinations. 5 We have previously reported that acadesine (5-aminoimidazole-4-carboxamide riboside, AICAR) induces apoptosis in B cells from B-CLL patients. 5 This apoptotic effect is caspase-dependent and p53-independent. Normal B lymphocytes are as sensitive as B-CLL cells to acadesine-induced apoptosis, while T lymphocytes are resistant. Here, we examine whether acadesine induces apoptosis in cells from other mature B-cell neoplasms.
After informed consent, peripheral blood samples of SMZL, MCL, and FL patients from the Hematology Unit at the Hospital Universitari de Bellvitge (Barcelona, Spain) were collected. Diagnosis was based on clinical, morphologic, immunophenotypic and molecular criteria following the WHO classification. 1 A total of 34 patients were included (21 SMZL, eight MCL and five FL). Eight of the 21 SMZL samples and six of the eight MCL samples were positive for CD5, determined by flow cytometry. All MCL samples were positive for cyclin D1 expression, as measured by immunohistochemistry. All FL samples were positive for CD10 and Bcl-2, negative for CD5, and all of them were low grade FL (with no transformation). All samples were positive for CD19, CD20 and presented clonality of surface immunoglobulins.
